Revelstoke Capital Partners completed the investment in AOM Infusion.

Revelstoke Capital Partners, a private equity firm, completed the investment in AOM Infusion, a specialty infusion provider focused on chronic therapy management. Financial terms were not disclosed. "AOM is committed to growth that enhances patient care. We are excited about the new partnership with Revelstoke, and we look forward to extending our reach by expanding our therapeutic focus areas, deepening our clinical expertise and ensuring that patients receive the highest quality infusion therapy in the most comfortable and cost-effective care settings," Keyur Mehta, AOM CEO.